79 related articles for article (PubMed ID: 21655657)
1. P16, c-erbB2 and Ki67 immunoexpression in urothelial carcinomas of the bladder.
Stepan A; Simionescu C; Mărgăritescu C; Ciurea R
Rom J Morphol Embryol; 2011; 52(2):653-8. PubMed ID: 21655657
[TBL] [Abstract][Full Text] [Related]
2. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
[TBL] [Abstract][Full Text] [Related]
3. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma.
Enache M; Simionescu C; Lascu LC
Rom J Morphol Embryol; 2012; 53(3):521-5. PubMed ID: 22990542
[TBL] [Abstract][Full Text] [Related]
4. Do different disorders in cell cycle regulation account for different biological behavior of urothelial and sinonasal inverted papillomas?
Gunia S; Fritzsche F; May M; Liebe D; Koch S
Pathobiology; 2008; 75(1):34-41. PubMed ID: 18334838
[TBL] [Abstract][Full Text] [Related]
5. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder.
Stepan A; Mărgăritescu C; Simionescu C; Ciurea R
Rom J Morphol Embryol; 2009; 50(3):461-5. PubMed ID: 19690775
[TBL] [Abstract][Full Text] [Related]
7. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
8. P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.
Walts AE; Lechago J; Bose S
Am J Surg Pathol; 2006 Jul; 30(7):795-801. PubMed ID: 16819320
[TBL] [Abstract][Full Text] [Related]
9. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases.
Lin O; Cardillo M; Dalbagni G; Linkov I; Hutchinson B; Reuter VE
Mod Pathol; 2003 Dec; 16(12):1289-98. PubMed ID: 14681330
[TBL] [Abstract][Full Text] [Related]
10. P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas.
Conscience I; Jovenin N; Coissard C; Lorenzato M; Durlach A; Grange F; Birembaut P; Clavel C; Bernard P
Eur J Dermatol; 2006; 16(5):518-22. PubMed ID: 17101472
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome.
Mylona E; Giannopoulou I; Diamantopoulou K; Bakarakos P; Nomikos A; Zervas A; Nakopoulou L
Eur J Surg Oncol; 2009 Feb; 35(2):197-201. PubMed ID: 18513919
[TBL] [Abstract][Full Text] [Related]
13. p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma.
Nakazawa K; Murata S; Yuminamochi T; Ishii Y; Ohno S; Nakazawa T; Kondo T; Katoh R
Am J Clin Pathol; 2009 Nov; 132(5):776-84. PubMed ID: 19846821
[TBL] [Abstract][Full Text] [Related]
14. Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers.
Brunner A; Verdorfer I; Prelog M; Mayerl C; Mikuz G; Tzankov A
Pathobiology; 2008; 75(1):25-33. PubMed ID: 18334837
[TBL] [Abstract][Full Text] [Related]
15. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.
Cheng J; Huang H; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Cancer Res; 2002 Jul; 62(14):4157-63. PubMed ID: 12124355
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
18. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices.
Ioachim E; Charchanti A; Stavropoulos N; Athanassiou E; Bafa M; Agnantis NJ
Anticancer Res; 2002; 22(6A):3383-8. PubMed ID: 12530091
[TBL] [Abstract][Full Text] [Related]
19. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
[TBL] [Abstract][Full Text] [Related]
20. EGFR and Her2/neu immunoexpression in papillary urothelial bladder carcinomas.
Enache M; Simionescu CE; Stepan A
Rom J Morphol Embryol; 2013; 54(1):137-41. PubMed ID: 23529321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
